New Challenges in the Differential Diagnosis of High-Grade Triple-Negative Breast Cancer and Serous Carcinoma

被引:1
|
作者
Puzyrenko, Andrii [1 ]
Cortina, Chandler S. [1 ]
Jorns, Julie M. [1 ]
机构
[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA
关键词
PAX8; triple-negative breast cancer; metastasis; serous carcinoma; PAX8; EXPRESSION; NEUROENDOCRINE TUMORS; NEOPLASMS; UTILITY; SITE; CELL;
D O I
10.1177/10668969221084268
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
While screening has improved early detection of primary breast cancers, it may also identify metastasis to the breast in rare instances. High-grade carcinomas identified on breast screening may have non-specific morphology and immunoprofiles, making distinction from metastasis problematic. High-grade carcinomas frequently lose expression of specific tumor markers. New evidence specifically challenges GATA3/PAX8 exclusivity in the differential diagnosis of high-grade triple-negative breast cancer and high-grade serous carcinoma of mullerian origin. This case series provides a careful and detailed review of immunohistochemistry interpretation, with focus on PAX8, and the potential pitfalls in making a definitive pathological diagnosis, which is essential in determining oncological treatment options.
引用
收藏
页码:728 / 733
页数:6
相关论文
共 50 条
  • [41] Vimentin as a poor prognostic factor for triple-negative breast cancer
    Yamashita, Nami
    Tokunaga, Eriko
    Kitao, Hiroyuki
    Hisamatsu, Yuichi
    Taketani, Kenji
    Akiyoshi, Sayuri
    Okada, Satoko
    Aishima, Shinichi
    Morita, Masaru
    Maehara, Yoshihiko
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (05) : 739 - 746
  • [42] New Therapeutic Strategies for Triple-Negative Breast Cancer
    Szekely, Borbala
    Silber, Andrea L. M.
    Pusztai, Lajos
    ONCOLOGY-NEW YORK, 2017, 31 : 13 - 20
  • [43] New Therapeutic Strategies for Triple-Negative Breast Cancer
    Szekely, Borbala
    Silber, Andrea L. M.
    Pusztai, Lajos
    ONCOLOGY-NEW YORK, 2017, 31 (02): : 130 - 137
  • [44] High-throughput "Omics" technologies: New tools for the study of triple-negative breast cancer
    Judes, Gaelle
    Rifai, Khaldoun
    Daures, Marine
    Dubois, Lucas
    Bignon, Yves Jean
    Penault-Llorca, Frederique
    Bernard-Gallon, Dominique
    CANCER LETTERS, 2016, 382 (01) : 77 - 85
  • [45] Nanobodies; new molecular instruments with special specifications for targeting, diagnosis and treatment of triple-negative breast cancer
    Bakherad, Hamid
    Ghasemi, Fahimeh
    Hosseindokht, Maryam
    Zare, Hamed
    CANCER CELL INTERNATIONAL, 2022, 22 (01)
  • [46] New insights into the discovery of drugs for triple-negative breast cancer metastasis
    Altei, Wanessa Fernanda
    Pachane, Bianca Cruz
    Souza, Cristiano
    Marques, Marcia Maria Chiquitelli
    Selistre-de-Araujo, Heloisa
    EXPERT OPINION ON DRUG DISCOVERY, 2022, 17 (04) : 365 - 376
  • [47] The Role of Breast Cancer Stem Cells in Chemoresistance and Metastasis in Triple-Negative Breast Cancer
    He, Lin
    Wick, Neda
    Germans, Sharon Koorse
    Peng, Yan
    CANCERS, 2021, 13 (24)
  • [48] Pembrolizumab and atezolizumab in triple-negative breast cancer
    Kwapisz, Dorota
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (03) : 607 - 617
  • [49] Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies
    Xiong, Nating
    Wu, Heming
    Yu, Zhikang
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [50] Epigenetic Therapies in Triple-Negative Breast Cancer: Concepts, Visions, and Challenges
    Lehmann, Ulrich
    CANCERS, 2024, 16 (12)